Lyra Therapeutics Inc (LYRA) Stock Price, Quote & News

Company Profile

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 393 4600

Website: lyratherapeutics.com

Address:

480 Arsenal Way, Watertown, United States

Vikingsstrade Oct. 3 at 7:37 PM

$TAOP $LYRA $ASPS $PLRZ Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

MoonCowBoy Oct. 3 at 12:45 AM

$LYRA $ASPS $PLRZ $FRGT (

0 · Reply

MoonCowBoy Oct. 3 at 12:45 AM

$APDN $EJH $TAOP $LYRA +

0 · Reply

StardustNdreams Oct. 2 at 8:14 PM

$LYRA almost 6% up today excellent to see here

0 · Reply

StardustNdreams Oct. 2 at 7:16 PM

$LYRA excellent move today

0 · Reply

1Spartantrade1 Oct. 2 at 6:39 PM

Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $APDN $EJH $TAOP $LYRA .

0 · Reply

Stmkr Oct. 2 at 5:26 PM

$LYRA Come on. Just do the offering to fund ph3 so this can start moving up

0 · Reply

wolfhowll Sep. 29 at 4:02 PM

$LYRA when does this get delisted?

1 · Reply

WallStVisions Sep. 24 at 1:41 PM

XPON has one of the most overlooked setups in small caps: — Lithium + battery exposure — Clean tech focus — Micro float — Chart is curling Volume + news = rapid move potential. Don’t miss it. $RCEL $LYRA $TCON $ARQT $UBX

0 · Reply

Rjinvestments88 Sep. 17 at 1:18 AM

$SPY $LYRA

0 · Reply

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 27, 2025, 8:00 AM EDT - 3 months ago

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Jun 16, 2025, 4:14 PM EDT - 3 months ago

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Jun 2, 2025, 8:29 AM EDT - 4 months ago

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Jun 2, 2025, 7:00 AM EDT - 4 months ago

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

May 7, 2025, 7:00 AM EDT - 5 months ago

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

May 6, 2025, 4:01 PM EDT - 5 months ago

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 13, 2025, 4:01 PM EDT - 7 months ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 4:01 PM EST - 11 months ago

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Sep 27, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 21, 2024, 9:14 AM EDT - 1 year ago

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

May 6, 2024, 7:59 AM EDT - 1 year ago

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Apr 30, 2024, 4:04 PM EDT - 1 year ago

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 28, 2024, 4:39 AM EDT - 1 year ago

3 'Buy-Rated' Biotech Stocks Under $10

ADMA GERN

Apr 26, 2024, 4:51 PM EDT - 1 year ago

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 1, 2024, 4:01 PM EST - 1 year ago

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2023, 4:01 PM EST - 2 years ago

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:00 AM EST - 2 years ago

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

Oct 10, 2023, 10:56 AM EDT - 2 years ago

Lyra Therapeutics: Hold For Phase 3 Topline

Oct 9, 2023, 1:20 AM EDT - 2 years ago

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 13, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

Jun 2, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at Jefferies Healthcare Conference

Jun 1, 2023, 7:29 AM EDT - 2 years ago

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

May 26, 2023, 7:57 AM EDT - 2 years ago

Lyra Therapeutics Announces $50.0 Million Private Placement

May 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

Apr 25, 2023, 7:59 AM EDT - 2 years ago

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Apr 5, 2023, 9:04 AM EDT - 2 years ago

Lyra Therapeutics: Negative EV With A Very Compelling Treatment For Chronic Rhinosinusitis In Phase 3

Mar 29, 2023, 4:06 PM EDT - 2 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 27, 2023, 7:59 AM EST - 2 years ago

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Feb 6, 2023, 7:56 AM EST - 2 years ago

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Nov 8, 2022, 4:01 PM EST - 3 years ago

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Sep 10, 2022, 8:00 AM EDT - 3 years ago

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Aug 29, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Aug 9, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 5, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Jul 5, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

May 26, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at Upcoming Investor Conferences

May 18, 2022, 12:46 PM EDT - 3 years ago

Lyra Therapeutics: Progress In The Clinic

Vikingsstrade Oct. 3 at 7:37 PM

0 · Reply

MoonCowBoy Oct. 3 at 12:45 AM

$LYRA $ASPS $PLRZ $FRGT (

0 · Reply

MoonCowBoy Oct. 3 at 12:45 AM

$APDN $EJH $TAOP $LYRA +

0 · Reply

StardustNdreams Oct. 2 at 8:14 PM

$LYRA almost 6% up today excellent to see here

0 · Reply

StardustNdreams Oct. 2 at 7:16 PM

$LYRA excellent move today

0 · Reply

1Spartantrade1 Oct. 2 at 6:39 PM

0 · Reply

Stmkr Oct. 2 at 5:26 PM

$LYRA Come on. Just do the offering to fund ph3 so this can start moving up

0 · Reply

wolfhowll Sep. 29 at 4:02 PM

$LYRA when does this get delisted?

1 · Reply

WallStVisions Sep. 24 at 1:41 PM

0 · Reply

Rjinvestments88 Sep. 17 at 1:18 AM

$SPY $LYRA

0 · Reply

Raymondsuper Sep. 9 at 10:42 PM

$LYRA sleeping giant keep buying before this wake up any good news will take this up 500% 🚀🚀🚀🚀🚀

2 · Reply

GluttonBoy Sep. 9 at 5:13 PM

TAIT stock is at zero borrow with shorts trapped and about to have a historic squeeze 3M float with no dilution and is a profitable semiconductor play Looking at $CISO $LYRA $HCAI $LICN $SLRX As well

1 · Reply

NVDAMillionaire Sep. 5 at 4:15 PM

$LYRA Great piece that accurately captures LYRA's current position. So if you want to refresh your understanding of LYRA or learn about LYRA for the first time, this is essential reading. https://beyondspx.com/quote/LYRA/lyra-therapeutics-enlighten-2-success-illuminates-a-path-forward-in-chronic-rhinosinusitis-nasdaq-lyra#analysis

0 · Reply

Stmkr Sep. 4 at 1:23 PM

$LYRA Could this already be priced in? Current market cap too low for a de-risked ph3 stage company in multi-billion $ indication. Next important news: - Securing funding for ph3 (hopefully through a single raise / partnership) - Guidance on timeline for completing a new ph3. Prior ph3s took 3 years, but I assume they can do better now + new trial will likely have a smaller sample size (maybe an interim analysis?) given focus on patients with >25% opacification + removal of daily saline irrigation from the protocol

0 · Reply

Stmkr Sep. 4 at 12:22 PM

$LYRA New trial needed. But new trial design pretty low risk (very high probability of success)

0 · Reply

joeycash_ Aug. 29 at 6:46 PM

$LYRA something big will happen soon

0 · Reply

wolfhowll Aug. 27 at 7:09 PM

$LYRA Any expectations?

1 · Reply

DougAfter60 Aug. 19 at 1:31 PM

$LYRA picked up some

0 · Reply

Rjinvestments88 Aug. 15 at 7:37 PM

$LYRA Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations. Looking ahead, revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Pharmaceuticals industry in the US.

0 · Reply

JarvisFlow Aug. 14 at 11:30 AM

HC Wainwright & Co. updates rating for Lyra Therapeutics ( $LYRA ) to Neutral, target set at 16.

0 · Reply

d_risk Aug. 13 at 6:18 AM

$LYRA - Lyra Therapeutics, Inc. - 10Q - Updated Risk Factors LYRA’s latest 10-Q risk factors spotlight deepening losses, major layoffs, failed LYR-210 trials, and urgent funding needs, while adding new warnings on acquisition uncertainty, regulatory hurdles, manufacturing risks, cybersecurity, stock volatility, and global instability. #Biotechnology #Cybersecurity #RegulatoryChallenges #FinancialRisk #ClinicalTrialFailure 🟢 Added 🟠 Removed https://d-risk.ai/LYRA/10-Q/2025-08-12

0 · Reply

Stmkr Aug. 12 at 8:57 PM

$LYRA

0 · Reply

Market Cap	11.51M
Revenue (ttm)	1.53M
Net Income (ttm)	-93.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,107.19%
Debt to Equity Ratio	0.00

Volume	11,400
Avg Vol	17,966
Day's Range	N/A - N/A
Shares Out	1.65M
Stochastic %K	99%
Beta	0.11
Analysts	Hold
Price Target	$11.50